Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.63 |
| ▸ | CA2 | P00918 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | TMPRSS4 | Q9NRS4 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11207523 | 0.98 | CA1 (0.61) | CA1CA2HSD17B10TSHRTMPRSS4 | |
| SCHEMBL2956458 | 0.82 | HSD17B10 (0.50) | CA1CA2HSD17B10TSHRTMPRSS4 | |
| SCHEMBL11102228 | 0.80 | CA1 (0.55) | CA1CA2HSD17B10TSHRTMPRSS4 | |
| SCHEMBL9586283 | 0.79 | TP53 (0.61) | CA1CA2HSD17B10TSHRHPGD | |
| Zinc Ion SCHEMBL11207528 | 0.78 | CA1 (0.59) | CA1CA2HSD17B10TSHRTMPRSS4 | |
| 5-Chlorosalicylic Acid SCHEMBL29499764 | 0.77 | CA1 (1.00) | CA1CA2HSD17B10TSHRTMPRSS4 | |
| 5-Chlorosalicylic Acid SCHEMBL130605 | 0.77 | CA1 (1.00) | CA1CA2HSD17B10TSHRTMPRSS4 | |
| SCHEMBL6715407 | 0.76 | CA12 (0.60) | CA1CA2HSD17B10TSHRALOX15 | |
| 5-Chlorosalicylic Acid SCHEMBL943143 | 0.76 | CA1 (0.96) | CA1CA2HSD17B10TSHRTMPRSS4 | |
| 5-Chlorosalicylic Acid SCHEMBL6855770 | 0.76 | CA1 (0.96) | CA1CA2HSD17B10TSHRTMPRSS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050119237-A1 | Non-malignant disease treatment with Ras antagonists | RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD. (IL) | 2005-06-02 | — | — | US | disclosed |
| EP-1187605-A4 | NON-MALIGNANT DISEASE TREATMENT WITH RAS ANTAGONISTS | THYREOS CORP (US) | 2004-05-26 | — | — | EP | disclosed |
| US-6462086-B1 | SUCH AS FARNESYLTHIOSALICYLIC ACID; INHIBITING PROLIFERATION OF T-CELLS; DIABETES, LUPUS, MULTIPLE SCLEROSIS; GRAFT REJECTION INDUCED BY FOREIGN ANTIGENS; CIRRHOSIS, RESTENOSIS | RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH AND INDUSTRIAL DEVELOPMENT LTD. (IL) | 2002-10-08 | — | — | US | disclosed |
| EP-1187605-A1 | NON-MALIGNANT DISEASE TREATMENT WITH RAS ANTAGONISTS | Thyreos Corporation (US) | 2002-03-20 | — | — | EP | disclosed |
| WO-2000078303-A1 | NON-MALIGNANT DISEASE TREATMENT WITH RAS ANTAGONISTS | THYREOS CORPORATION (US) | 2000-12-28 | — | — | WO | disclosed |
| US-5766556-A | SUITABLE ENVIRONMENT FOR SIMULTANEOUS SYNTHESIS OF ORGANIC COMPOUNDS, INORGANIC COMPOUNDS AND ORGANOMETALLIC COMPOUNDS | WARNER-LAMBERT COMPANY (US) | 1998-06-16 | — | — | US | disclosed |
| US-5714127-A | RESERVOIR RACKS WITH REACTION WELLS; GAS DISPERSION TUBES CONTAINING FILTERS; HOLDER BLOCK WITH APERTURES; MANIFOLD | WARNER-LAMBERT COMPANY (US) | 1998-02-03 | — | — | US | disclosed |
| US-5702672-A | REACTION TUBE COMPRISING GAS DISPERSION TUBE HAVING GROUNG GLASS JOINT SECTION | WARNER-LAMBERT COMPANY (US) | 1997-12-30 | — | — | US | disclosed |
| US-5612002-A | SYNTHESIS OF COMPOUNDS | WARNER-LAMBERT COMPANY (US) | 1997-03-18 | — | — | US | disclosed |
| US-5593642-A | CONTAINMENT OF SOLID SUPPORT WITHIN A GAS DISPERSION TUBE | WARNER-LAMBERT COMPANY (US) | 1997-01-14 | — | — | US | disclosed |
| US-5324483-A | Apparatus for multiple simultaneous synthesis | WARNER-LAMBERT COMPANY (US) | 1994-06-28 | — | — | US | disclosed |
| WO-1994008711-A1 | APPARATUS AND METHOD FOR MULTIPLE SIMULTANEOUS SYNTHESIS | WARNER-LAMBERT COMPANY (US) | 1994-04-28 | — | — | WO | disclosed |
| CN-1007153-B | PREPN. OF BENZOTHIOPHENES AND BENZOFURANS HAVING ANTIALLERGY ACTIVITY | WARNER LAMBERT CO (US) | 1990-03-14 | — | — | CN | disclosed |
| US-4663344-A | ANTIPYRETICS, ANTIARTHRITIC AGENTS | MERCK & CO., INC. (US) | 1987-05-05 | — | — | US | disclosed |
| CN-85109587-A | Have the new benzothiophene kind of antiallergic activity and the preparation method of benzofuran compounds | — | 1986-12-17 | — | — | CN | disclosed |
| EP-0187487-A1 | Benzothiophenes and benzofurans having antiallergic activity | WARNER-LAMBERT COMPANY (US) | 1986-07-16 | — | — | EP | disclosed |
| EP-0026000-B1 | SPIRO COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Takeda Chemical Industries, Ltd. (JP) | 1983-05-11 | — | — | EP | disclosed |
| US-4362740-A | ANTICOAGULANTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1982-12-07 | — | — | US | disclosed |
| EP-0026000-A1 | Spiro compounds, process for their preparation and pharmaceutical compositions containing them | Takeda Chemical Industries, Ltd. (JP) | 1981-04-01 | — | — | EP | disclosed |
| US-3953595-A | Substituted benzoic acid hypolipemic agents | PFIZER INC. (US) | 1976-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119237-A1 | Non-malignant disease treatment with Ras antagonists | RSU1, KSR1, KRAS | CA1 3526/4885CA2 4378/4885HSD17B10 4164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.